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1. Introduction
Cystic Fibrosis (CF) is the most common fatal autosomal recessive genetic disease in the
Caucasians with a frequency of approximately 1 in 2500 newborns (Cystic Fibrosis Founda‐
tion, http://www.cff.org/). It affects several organs including the lungs, the liver, the pan‐
creas, the sweat glands and the gastrointestinal and reproductive tracts [1]. The most severe
complications that finally lead to death are those in the airway epithelium [2]. Continuous
secretion of mucus causes blockage of the lungs by thick sputum and also makes the lungs
susceptible to secondary bacterial infections. Subsequent inflammatory responses by the im‐
mune system damage the lungs and the combination of all these factors leads to cardiac fail‐
ure and to death [3].
The primary defect at the biochemical level that is responsible for the symptoms in the lung
was found to involve cAMP-mediated chloride ion (Cl-) conductance. Specifically, mutations
in the gene that encodes a cAMP-regulated Cl- channel in the apical membrane of epithelial
cells are the cause of cystic fibrosis. This gene was identified, cloned and named the Cystic
Fibrosis Transmembrane conductance Regulator (CFTR) [4, 5]. Though the exact mechanism
of pathogenesis is not fully confirmed, the prevailing theory supports that absence or dra‐
matic decrease in the amount of functional CFTR protein at the airways epithelium results
in reduced chloride secretion, increased sodium reabsorption and therefore in insufficient
airway luminal fluid due to osmosis [6]. These alterations in the respiratory epithelium sub‐
sequently result in deficient mucus clearance which determines chronic cycles of bacterial
infections and inflammation [6]. In addition, the formation of thick stationary mucus traps
neutrophils that might otherwise clear the infection [7].
© 2013 Kotzamanis et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
For several reasons including the easy access to the respiratory tract without any interven‐
tion procedures, the cloning and the characterization of the CFTR gene and the expectation
that even relatively low levels of expression of the gene may have a therapeutic outcome [8],
Cystic Fibrosis became an ideal target for gene therapy and an example for gene therapy of
other lung diseases. Indeed, the first gene therapy clinical trials for CF started in 1993 and 29
clinical trials have been conducted since then (http://www.wiley.com/legacy/wileychi/
genmed/clinical/). Several trials have demonstrated gene transfer and transgene expression.
In some cases, low levels of transient correction of Cl- ion transport deficiency has been ob‐
served but overall, no clinical improvement has been achieved. The histological, immuno‐
logical and intracellular barriers that exist in the lung have proven to be more difficult to
overcome than what was initially thought. The purpose of this chapter is to analyze these
barriers and to present the challenges the gene therapist is faced with when targeting the
lung for the treatment of CF.
First, the basic histology of the lung will be described so that the reader can identify the po‐
tential target cells for CF gene therapy and realize the complexity of the lung structures that
the gene transfer agent needs to penetrate in order to reach these target cells.
2. Basic histology of the lung
The lung is a complex organ that is divided into the air-conducting portion consisting of the
trachea, the bronchi and the bronchioles and the respiratory portion consisting of the alveoli,
which is the place of gas exchange (Figure 1).
Figure 1. Schematic illustration of the lung.
The trachea and most of the bronchi are covered by pseudostratified columnar ciliated epi‐
thelium (known as the respiratory epithelium). Columnar ciliated cells are the predominant
population extending from the basal lamina to the airway lumen. Other cells facing the lu‐
men are the nonciliated Goblet cells which produce mucin polymers [9], forming a thin layer
of mucus that covers the airway epithelium. The role of the airway mucus is to trap inhaled
particles which are then transferred out of the lung by cilia beating and/or cough. The effec‐
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tiveness of this action depends on the viscosity of the mucus which is determined by the lev‐
el of its hydration [10]. Normal airway mucus consists of 97% water [11] but when luminal
fluid is reduced, as in CF, the clearance of mucus by cilia and cough is also reduced. Under
the basal lamina lies the lamina propria, which consists of elastic fibers and hosts the sub‐
mucosal glands that together with the Goblet cells produce components of the mucus [9]
(Figure 2A,B,C).
Several stem cells populations responsible for the maintenance of the respiratory epithelium
have been identified in the lung. Specifically, a population of basal cells, residing at close
proximity to the underlying basal lamina in the larger airways, has been shown to have a
high multipotency potential allowing regulation of the epithelium homeostasis under nor‐
mal circumstances or after injury [12]. Another type of cells with stem-cell-like properties is
the Clara cells. These nonciliated cells are located at the terminal bronchioles and produce a
solution similar to the surfactant in the alveoli. Interestingly, Clara cells can multiply and
differentiate into ciliated cells to regenerate the bronchiolar epithelium [13].
The respiratory portion of each lung consists of approximately 300 million alveoli. Each al‐
veolus has a thin wall consisting mainly of type I and type II alveolar cells (Figure 2D). Type
II alveolar cells are responsible for the secretion of a thin layer of fluid that normally coats
the alveolar surface in order to decrease the surface tension at the air-fluid interface, the sur‐
factant. Surfactant turnover is mediated by the phagocytic function of alveolar macrophag‐
es, which are also located in the alveolar wall and are frequently seen in the alveolar lumen.
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Figure 2. A) Upper respiratory tract section, B) Epithelium of upper respiratory tract, C) Mucus produced in Goblet cells
and secreted in the lumen, D) Alveolar section.
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It  is not yet clear which of these cells are the target for gene therapy of Cystic Fibrosis.
In healthy individuals there is little CFTR expression in the lung, except the submucosal
glands and epithelial cells at the small airways where higher expression is observed [14].
Early studies suggested that the submucosal glands are the site of maximal CFTR expres‐
sion [15], but more recent data suggested that this may be the ciliated surface epithelium
of  the  bronchioles  [16].  This  uncertainty  is  one  of  the  main  obstacles  for  successful  CF
gene therapy. Depending on which are the cells that need to be corrected, different ana‐
tomical  or  immunological  barriers  apply and therefore different  administration methods
have to be used.
3. Physical barriers to gene transfer to the lung
As most formulations administered to treat CF, including gene transfer agents, are deliv‐
ered  directly  to  the  airways  in  the  form of  aerosols  [17],  the  first  physical  barrier  that
needs to be overcome before the transgene reaches the target cells is the airways mucus.
Trapping in the mucus and clearance by cilia is the main factor reducing transfection ef‐
ficiency in lung cells of all individuals. In Cystic Fibrosis, the lungs are progressively fil‐
led  with  large  amounts  of  purulent  secretions,  the  sputum,  which  consists  of  mucus,
DNA,  actin,  cell  debris  and inflammatory  cells  [18].  The  most  commonly  used  in  gene
therapy for CF viral vectors and non-viral liposomal vectors have been proven unable to
penetrate  the  CF  sputum  [19,  20],  suggesting  that  effective  treatment  may  be  achieved
only at  early stages of  the disease before the lungs are filled with sputum [21].  Several
improvements can be made at this stage to increase transfection efficiency, such as use of
methylcellulose  gel  formulations  to  inhibit  mucociliary  clearance  [22]  or  of  mucolytics
[23, 24], but these need to be validated in clinical trials.
The second physical barrier to gene transfer to the airway epithelium is the composition of
the apical surface of the cells. First, the presence of specific receptors determines the kind of
viral vector to be used. For example, adenoviral vectors have low transfection efficiency due
to the low abundance of the required receptors on the apical side of most human airway epi‐
thelial cells [25] and this is one of the reasons why they are not considered in clinical trials
any more [21]. Making the basolateral membrane, which is more abundant in adenoviral re‐
ceptors [25], accessible to the adenoviral vector has been proposed as an attractive alterna‐
tive. Indeed, the use of agents such as sodium caprate that can cause transient dissociation
of tight junctions, impressively increases transgene delivery and expression in animal mod‐
els [26, 27] but may not have a clinical application due to the risk of systemic bacterial inva‐
sion. Second, the glycocalyx on the apical membrane seems to interfere with the interaction
between adenovirus and its few receptors [28]. Removal of sialic acid residues from the gly‐
cocalyx by pretreatment with neuraminidase may be an effective way to overcome this
physical barrier [28].
Although non-viral vectors are not affected by the problems described above, they are sub‐
ject to possible destruction by the cell defence mechanisms against foreign DNA invasion.
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These mechanisms have evolved to secure the host cell’s genetic integrity but in gene thera‐
py they constitute one more hurdle to overcome. Indeed, once the therapeutic DNA enters
the target cells in the lung of CF patients, it faces a series of intra-cellular barriers that apply
to gene therapy in general and not just to gene therapy for CF. These barriers include degra‐
dation by cytosolic nucleases [29, 30] and degradation inside digestive lysozomes formed by
transformation of endosomes following endocytosis [31]. Several methods have been imple‐
mented so that the transgene can escape the endosomes after internalization. Cationic lipids
and polycationic polymers like polyethylenimine (PEI) [32] utilised as chemical vectors in
complexes with the transfected DNA, protect it from nucleases and enable it to escape the
endosomes. Such complexes carrying the CFTR gene have been used to correct the ion trans‐
port defect in CF transgenic mice [33] and are currently being tested in clinical practice [34].
Other strategies to protect the therapeutic DNA from the endosomes and therefore to in‐
crease the transfection efficiency include the use of pharmacological endosomelytic agents
such as chloroquine [35], endosome-disrupting peptides [36-38] and glycerol [39]. All these
aim at destabilizing the endosomal membrane so that the contents are released intact to the
cytosol but may be of limited clinical value due to safety concerns in the host cells.
The final physical barrier before the CFTR transgene enters the nucleus of the non-dividing
airway epithelial cells and undergoes transcription is the nuclear envelope [40]. Many viral
vectors can efficiently deliver their cargo in the nucleus by exploiting the nuclear transport
systems of the host [41], but non-viral vectors are in most cases ineffective in front of the nu‐
clear envelope. Strategies such as the use of chemical vectors based on PEI [42] and of Nu‐
clear Localization Signals (NLS) which are integrated into the transfected DNA and bind to
transporter proteins in order to facilitate nuclear entry [43, 44] have been implemented and
found to promote nuclear delivery in vitro. However, these have not been validated with
large therapeutic genes like the CFTR and in non-dividing cells in vivo and may not be of use
for gene therapy for CF [45].
4. Immunological barriers to gene transfer to the lung
Apart from the extracellular and intracellular barriers described above, there is a second line
of defence consisting of specific and non-specific immune responses that protect the lung
cells against foreign particles which are present in the air. During gene therapy for CF, these
immunological mechanisms can be activated by the vector carrying the transgene or the
product of the transgene and therefore limit the overall efficacy [46].
Various immunological responses are directed against the carrier of the therapeutic gene be‐
fore this enters the target cells. Pulmonary macrophages have been shown to ingest adeno‐
viral vectors, but when they were removed before transfection, an increase in transgene
expression was observed [47]. Furthermore, humoral immune responses mediated by helper
T lymphocytes result in the production of neutralizing antibodies against the vector, which
restricts the possibility of re-administration and so, the use of most viral vectors for the
treatment of chronic diseases such as CF [46].
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Other responses are initiated after the transgene is delivered to the lung cells. Particularly
when viral vectors are used, cellular immune responses mediated by cytotoxic T lympho‐
cytes eliminate transduced cells expressing viral proteins resulting in parallel loss of trans‐
gene expression [46]. Although in theory non-viral vectors are not associated to such
problems as they are less immunogenic than viral vectors, in practice they are usually used
in combination with ligands so that they overcome the physical barriers described above
and this can provoke immunological reactions similar to those caused by viral vectors [46].
In addition, viral and non-viral vectors can provoke the release of host cytokines which have
been shown to inhibit expression of the gene delivered if this is driven by a common viral
promoter [48].
Several approaches have been developed to overcome the immunological barriers in the
lung. The use of immunosuppressant drugs such as cyclophosphamide have been proved
very effective in mice allowing both prolonged transgene expression and repeated adminis‐
tration of an adenoviral vector [49]. Similar results were obtained with corticoid steroids
such as dexamethasone [50] and budesonide [51] which were found to decrease inflamma‐
tion mediated by viral vectors. Other strategies include the co-administration of IL-12 [52]
and blockade of CD4+ T cells [53-56]. However, all these approaches are likely to cause more
damage than benefit, considering that the lungs of CF patients are colonized by pathogenic
bacteria, and so they are not applicable in the clinical setting.
On the other hand, non-viral chemical vectors based on cationic lipids can be re-adminis‐
tered without the need to be combined with immunosuppressants [57]. From that aspect,
these are safer than viral vectors for gene therapy of CF but still not absolutely harmless as
they have been associated with lung toxicity due to provocation of inflammation [58]. An‐
other mediator of inflammation in the lung can be the CpG motifs on the bacterial plasmid
DNA which is usually used to clone the therapeutic gene in non-viral gene therapy [59, 60].
Unlike eukaryotic DNA, this dinucleotide is relatively unmethylated in bacteria and can be
inflammatory through recognition by toll-like receptor 9 on B cells [61]. As methylation of
the CpG motifs prior to gene delivery may decrease the expression of the transgene, the ex‐
clusion of any bacteria-derived DNA from the therapeutic construct is a more promising al‐
ternative.
5. Safety concerns
Immunological responses elicited by a gene therapy vector do not only pose a barrier to effi‐
cient delivery and expression of the therapeutic gene in the target cells but more important‐
ly, they can raise very serious safety issues. This lesson has been learned from a gene
therapy human trial where lethal complications were experienced [62]. In that study, an ade‐
noviral vector containing the cDNA of the gene encoding ornithine transcarbamylase (OTC)
was administered to 18 patients with partial OTC deficiency, a disease caused by a defect in
urea synthesis. The adenoviral vector provoked immunologic and other side effects, such as
fever, myalgia and nausea in 17 out of the 18 participants but the 18th patient developed a
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serious immune response to the vector that eventually led to his death 98 hours after admin‐
istration [62]. This death was a setback for all gene therapy clinical studies using viral vec‐
tors, as human immune responses cannot be predicted pre-clinically. Apart from the
immunological responses caused by the vector, other unfortunate events of different nature
have also been found to be associated with reduced safety. Treatment of patients with X-
linked severe combined immune deficiency (SCIDX1) using a retroviral vector carrying the
γc gene resulted in the correction of the disease and huge enthusiasm about the future of
gene therapy [63]. However, two of the cured patients developed a leukemia-like condition
2-3 years later due to disruption of an endogenous oncogene by integration of the vector [64,
65]. Since vector integration is usually random and uncontrollable, insertional mutagenesis
is a general problem that all integrating vectors have. As these problems also apply to most
vectors used in gene therapy for Cystic Fibrosis, avoiding unwanted immune response and
insertional mutagenesis are two major challenges for the genetic treatment of CF. Strategies
to respond to the second challenge of insertional mutagenesis will be discussed in the next
section. To address the first problem, the solution is to use less immunogenic vectors.
Although adenoviral vectors administered systemically can cause acute and potentially life-
threatening cytokine response [66] their local administration at mild doses to nose and lung
tissues did not result in such unacceptable safety profile [34]. However, extensive use of
these vectors during the early times of CF gene therapy has shown that cellular and humoral
immune responses against the virus are generated and these limit repeated administration
[67, 68]. Another approach to avoid immunologic reactions from the host is to coat the virus
capsid with polyethylene glycol (PEG). Such PEGylated viruses, called “stealth viruses”, are
not recognised by the immune system and can significantly prolong transgene expression
[69]. A less immunogenic alternative to adenoviral constructs is the use of adeno-associated
virus (AAV) vectors. Indeed, several human CF trials with AAV vectors have confirmed
their good safety profile albeit with low transduction efficiency [70-74].
Despite significant progress made towards the generation of safer viral vectors [75], non-vi‐
ral synthetic vectors containing only human DNA sequences are the vectors of choice when
safety is considered as first priority. These vectors generally consist of the therapeutic DNA
either naked or mixed with chemical compounds, like cationic lipids or cationic polymers
[76]. Naked DNA is in theory the safest gene therapy agent but very difficult to be intro‐
duced into the target cells. Several physical methods have been developed to facilitate DNA
entry into the lung of living animals, such as the use of electrical pulses (electroporation)
[77], of ultrasound waves (sonoporation) [78] and of magnetic fields (magnetofection) [79]
but none of them has reached the clinical use yet. On the other hand, chemical carriers have
rapidly been developed and used in 6% (n=110) of gene therapy clinical trials (http://
www.wiley.com/legacy/wileychi/genmed/clinical). These act by forming complexes with the
negatively charged DNA. The complexes condense the DNA, protect it from nucleases, al‐
low its entry into the cells and protect it from the endosomes [80]. Indeed, local administra‐
tion of cationic lipid/CFTR-plasmid-DNA complexes in an aerosol formulation to the lungs
of cystic fibrosis transgenic mice resulted in correction of the ion transport defect [33]. Simi‐
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lar studies in human patients demonstrated some transgene expression, but not at sufficient
levels to provide a clinical benefit [57, 81-86].
6. Duration of transgene expression
Provided that all obstacles to gene delivery to the lung are overcome and the CFTR trans‐
gene finally reaches the target cells, a clinical benefit for CF can only be achieved by lifelong
expression of the gene. As repeated administration is in most cases restricted by immune re‐
sponses generated by the patient against the vector, other strategies have been employed for
efficient retention and long-term expression.
Integration into the host genome has widely been used in gene therapy to fulfil this require‐
ment. However, the dangers of integration due to insertional mutagenesis have become a
widely publicised issue as a result of the SCIDX1 clinical trial, where some patients devel‐
oped leukaemia due to deregulation of the growth-promoting LIM domain only 2 (LMO2)
proto-oncogene caused by integration of the vector [64, 65]. The safety concerns regarding
uncontrolled integration of the therapeutic gene into the host genome have been strength‐
ened by observations that there is a preference of integrating vectors for the regulatory re‐
gions of transcriptionally active genes [87]. Given the need for long-term expression and the
problems associated with vector integration, vectors that persist in the nucleus by being
maintained episomally without integrating, could be highly advantageous. Among the sys‐
tems developed to achieve extra-chromosomal maintenance of the vectors carrying the ther‐
apeutic gene, two are considered safe enough for clinical application in the future: artificial
chromosomes and systems based on scaffold/matrix attachment region (S/MAR).
Human Artificial Chromosomes (HACs) are vectors able to replicate and segregate in paral‐
lel with the endogenous chromosomes in human cells. To achieve this, they must contain
the minimal elements required for chromosome function, namely an origin of replication, te‐
lomeres and centromeres [88]. HACs can be generated by a method similar to the one ap‐
plied for YAC construction in yeast and involves assembling the functional chromosomal
elements and building up a HAC de novo in human cells. Different strategies have been fol‐
lowed to generate de novo HACs, the most convenient of which is to transfect a BAC carry‐
ing only a large array of α-satellite (alphoid) DNA and some marker genes into HT1080
cells[89]. HACs generated this way exist as single (or low copy) chromosomes in the nucleus
and have a high mitotic stability (close to 100%) in the absence of selection. The potential use
of these vectors in gene therapy has been demonstrated by expression of large therapeutic
genes from them [90, 91].
S/MARs are diverse sequences found in all eukaryotic genomes where they are involved in
many aspects of chromatin function such as organization of chromatin into loops, which
seems to be mediated by the interaction between S/MARs and the nuclear matrix [92]. Vec‐
tors containing an S/MAR element have the ability to remain episomally at low copy num‐
ber for more than 100 generations in the absence of selection and with a mitotic stability of
98% [93]. This ability has been demonstrated in several cell lines and in primary cells [94]
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and also in vivo in genetically modified pigs [95] making them very attractive for use in CF
clinical trials.
An alternative to the use of episomal vectors described above, that still satisfies both re‐
quirements for permanent transgene expression and elimination of genotoxic effects is the
controlled integration of the therapeutic DNA at a specific site in the host genome where no
active genes are present. Several vector systems have been developed to achieve this, with
each one of them having its own limitations [96]. From these, vectors based on the ΦC31 in‐
tegrase [97] and on transposase enzymes [98] are the most promising for use in CF gene
therapy as they have a preference for specific sequences that already exist in the human ge‐
nome and have been shown to work in vivo.
An additional problem to achieving long-term expression of the CFTR transgene delivered
to the lung is the life span of the target cells. Depending on the rhythm of natural turnover
of these cells, transgene expression can last for as long as these cells are alive. A more effec‐
tive approach would be to either target putative stem cells with the capacity to differentiate
to airway epithelial cells [34] or to deliver exogenous heterologous or corrected autologous
stem cells to the lungs of CF patients ex vivo [99].
Airway basal stem cells are a candidate target for CF stem cell therapy. However, the facts
that this population is estimated to represent only a minor part of the total airway epitheli‐
um [12] and that it is quite inaccessible as it is not exposed to the airway lumen make such a
therapy approach very challenging.
Ex vivo gene therapy using stem cells may not only provide permanent cure without the
need for re-administration, but also solve the hurdle of the low in vivo gene delivery efficien‐
cy. In ex vivo cell therapy using Embryonic Stem Cells or foetal Mesenchymal Stem Cells
from a healthy embryo there is no need for transfection of a therapeutic gene. However,
these stem cells are used in an allogeneic fashion which requires the parallel use of immuno‐
suppressive drugs and are therefore not applicable for the treatment of CF. A more attrac‐
tive strategy would be the transfer of the CFTR gene to patient-derived autologous stem
cells such as Mesenchymal Stem Cells (MSCs), which can easily be isolated from the bone
marrow or adipose tissue of adults [100] or Induced Pluripotent Stem Cells that can be gen‐
erated by reprogramming of adult somatic cells [101, 102]. In that case, the transfection pro‐
cedure would be performed in vitro before reimplantation of the cells back to the donor,
which is far more efficient than in vivo delivery. Furthermore, bone marrow-derived MSCs
have been shown to be able to express transgenes [103] and to differentiate to several types
of cells including airway epithelial cells [104]. Nevertheless, there is little literature on how
the ex vivo corrected MSCs can be administered and engrafted in the lung of Cystic Fibrosis
patients. Both systemic and topical lung administration of bone marrow-derived cells have
been applied and shown to result in some engraftment into the airways [105], but there are
several challenges to be addressed, before ex vivo cell therapy becomes part of the CF clinical
research. These challenges include the very low efficiency of engraftment (<1%) and the fact
that previous damage to the surface epithelium caused by epithelia-injuring reagents seems
to be required for the engraftment [75].
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7. Pattern of transgene expression
For gene therapy of some diseases it is important to achieve expression of the therapeutic
gene at specific levels. Expression at lower levels than normal might not be sufficient to cor‐
rect the defect and at higher levels could result in undesirable effects. In other cases, tissue-
specific expression may be very important. The elements responsible for controlled and
tissue-specific expression of a gene usually lie within the introns and the sequences before
and after the gene. Therefore, the use of genomic constructs which contain the introns and
flanking DNA of the therapeutic gene is expected to be more effective than that of mini-
gene/cDNA constructs in gene therapy for certain genetic diseases where precise levels of
the gene product are required [88]. There is evidence that CF is such a disease.
Although some studies have shown that expression of as little as 5-10% of endogenous
CFTR levels may suffice to observe a clinical benefit [106], other studies have shown that dif‐
ferent functions of CFTR like Cl- transport and Na+ absorption, when they are abnormal they
can be restored by different levels of CFTR expression [107]. Moreover, restoration of mucus
transport at normal rates requires transduction of at least 25% of target cells [108]. These da‐
ta indicate that CF gene therapy may require CFTR expression at the right levels, at the right
time and in the right population of cells, which can be achieved only if it is driven and con‐
trolled by the gene’s natural promoter and regulatory elements present on a genomic thera‐
peutic construct.
The  CFTR  gene  is  located  on  chromosome  7,  is  200-250  kb  long  [5]  and  comprises  27
exons. It shows a tightly regulated temporal and spatial pattern of expression [109, 110],
which was not found to be regulated by any tissue-specific regulatory elements, suggest‐
ing  that  other  elements  outside  the  proximal  promoter  are  probably  involved  in  tissue
specific  regulation of  transcription.  Several  DNase I  Hypersensitive Sites  (DHS),  usually
associated  with  regulation  of  transcription,  have  been  identified  across  400  kb  of  DNA
flanking the CFTR gene. These lie 5’ to the gene at -79.5 and -20.9 kb with respect to the
translation start site [111], in introns 1 [112], 2,  3,  10, 16, 17a, 18, 20 and 21 [113] and 3’
to the gene at +5.4, +6.8, +7, +7.4 and +15.6 kb [114]. Most of these DHS have been found
to  be  involved  in  tissue-specific  CFTR  expression  [114-117].  Therefore,  a  large  genomic
construct spanning ~300 kb from the -79.5 kb to the +15.6 kb DHS would include all the
known long-range controlling elements of  the CFTR  gene and should give full  levels of
tissue specific expression which would be advantageous for gene therapy of cystic fibro‐
sis. This big in size region has recently been cloned on a single Bacterial Artificial Chro‐
mosome (BAC) vector and is currently available [118].
As the majority of recombinant viruses, commonly utilized as carriers for transfer of plas‐
mid DNA, apart from evoking unwanted immune responses, have a maximum packaging
capacity and cannot be used to deliver large genomic-DNA-containing constructs, gene ther‐
apy using genomic loci of therapeutic genes should be non-viral. This restriction raises again
the issue of efficiency of delivery which is even more challenging to deal with than when
using smaller constructs.
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8. Clinical research for cystic fibrosis
Gene therapy clinical trials for CF started in 1993 and over 26 viral and non-viral trials have
been conducted or are in progress to date. Viral trials were based on engineered adenovirus
and adeno-associated virus and non-viral on various cationic lipids, with GL67 being the
most predominant. The references for the published studies are listed in Table 1.
Adenoviral clinical trials AAV clinical trials Non-viral clinical trials using cationic lipids
Zabner et. al., 1993 [119] Wagner et. al., 1999 [120] Sorcher et. al., 1994 [121]
Crystal et. al., 1994 [122] Aitken et. al., 2001 [70] Caplen et. al., 1995 [82]
Boucher et. al., 1994 [123] Wagner et. al., 2002 [74] Gill et. al., 1997 [83]
Knowles et. al., 1995 [124] Flotte et. al., 2003 [71] Porteous et. al., 1997 [84]
Hay et. al., 1995 [125] Moss et. al., 2004 [73] Zabner et. al., 1997 [86]
Zabner et. al., 1996 [68] Moss et. al., 2007 [72] Alton et. al. 1999 [81]
Bellon et. al., 1997 [126] Hyde et. al., 2000 [57]
Harvey et. al., 1999 [67] Noone et. al., 2000 [127]
Zuckerman et. al., 1999 [128] Ruiz et. al., 2001 [85]
Joseph et. al., 2001 [129]
Perricone et. al., 2001 [130]
Table 1. List of CF gene therapy clinical trials.
The trials have confirmed several of the safety concerns associated to the use of viral vec‐
tors.  However,  other challenges and questions raised pre-clinically still  remain to be an‐
swered.  In  general,  proof-of-principle  for  gene  transfer  to  the  airways  has  been
demonstrated by transgene expression or partial  correction of the Cl-  transport defect in
some of the trials but clinically meaningful outcomes such as improvement in pulmonary
function and decrease of  bacterial  colonies have not been clearly shown in any.  In con‐
trast, poor results with regards to clinical benefit, obtained so far, revealed another chal‐
lenge in  CF clinical  research.  This  is  the  need to  develop more accurate  tools  to  assess
gene transfer efficacy at the clinical level [34].
Historically, adenoviral vectors were the first to be used. However, due to the absence of ad‐
enoviral receptors on the apical side of most human airway epithelial cells [25], which re‐
sults in low transduction efficiency, and due to induction of immune responses that exclude
repeated administration [67, 68], adeno-associated viral vectors became an alternative. These
vectors were soon found to have their own problems. First it is their small packaging capaci‐
ty which barely holds the whole human CFTR gene and therefore restricts the use of strong
promoters. Then, at least serotype 2 AAV vectors that were used in initial studies could not
be re-administered due to stimulation of immune reactions [72, 73]. Suggestions made to
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overcome these limitations still need to be validated in humans. Non-viral vectors were
found compatible with repeated administration [57], but their efficiency were variable and
transgene expression was shown only in some studies. In addition, flu-like symptoms were
reported [81, 85], which were associated to the presence of unmethylated CpG motifs on the
plasmid DNA that was delivered. The use of genomic constructs containing only human
DNA may overcome this limitation but this also needs to be shown in future clinical trials.
9. Conclusion
Almost 20 years have passed since the beginning of gene therapy trials for CF. Despite ini‐
tial enthusiasm, only little progress has been made during that time. In contrast, the main
conclusion was that the lung is more difficult to target than initially anticipated. Several bar‐
riers were discovered, which led to the development of respective ways to overcome them.
The majority of these have not reached the level of validation in clinical trials yet. For exam‐
ple, the use of a non-viral vector with the ability to remain extra-chromosomally containing
the whole genomic region of the CFTR gene or ex vivo stem cell therapy, are two promising
approaches that need to be further explored and may be seen in clinical trials in the future.
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